Ruxolitinib for the Treatment of Steroid-Refractory Chronic Graft-vs-Host Disease—Another Hopeful Step Forward

AccessHope’s Vice President and Executive Clinical Director Joseph Alvarnas, MD, published a study in JAMA Network Open highlighting the use of a new treatment for the potentially life-ending chronic graft-vs-host disease (cGVHD) resulting from allogeneic hematopoietic stem cell transplantation (HSCT). The study progressively found that integrating evidence-based advances in the multidisciplinary care management of patients with cGVHD by a coordinated expert care team may lead to more-effective, personalized care solutions for this unique population.